A lack of toxicity of the AmBisome formulation was noted in both studies.
2
There were no breakthrough fungal infections during empirical therapy with AmBisome.
3
AmBisome followed a nonlinear dosage relationship that was consistent with reticuloendothelial uptake and redistribution.
4
The pharmacokinetic parameters of AmBisome were measured as those of amphotericin B by high-performance liquid chromatography.
5
AmBisome administered as a 1-h infusion in this population was well tolerated and was seldom associated with infusion-related toxicity.
1
Elan shareholders have approved the sale of its anti-fungal drug Abelcet for $370 million at an egm held today.
2
Elan has won shareholder approval for the $370 million (€366.37 million) sale of the rights to its Abelcet treatment to US company Enzon.
3
Elan's asset sale to pay its huge debt grossed $370 million today with the disposal of an anti-fungal drug Abelcet for $370 million.
1
We initiated intravenous administration of amphotercin B.
1
Time of treatment with Amph B was prolonged from 13 to 30 days and that with 5FC from 11 to 40 days.
1
High-dose liposomalamphotericinB was effective and safe in the treatment of neonatal candidiasis.
2
LiposomalamphotericinB is very effective and safe but currently unaffordable because of its high price.
3
This association of renal and hepatotoxicity with liposomalamphotericinB has not previously been reported in children.
4
LiposomalamphotericinB was always more active than the other drugs against all the microorganisms except C. bertholletiae.
5
Fungal eradication was more rapid in patients treated early with high doses and in patients who received high-dose liposomalamphotericinB as first-line therapy.
1
Single-dose acute toxicity of the AmB microemulsion was studied on male albino Webster-derived CD-1 mice and compared with Fungizone.
1
Similar combinations of NP-1 and amphotericinB, however, did not yield synergy.
2
Only amphotericinB was statistically superior to controls with regard to mortality.
3
However, data on agar-based tests for itraconazole and amphotericinB are yet scarce.
4
Treatment consisted in systemic amphotericinB combined with surgical debridement in 3 cases.
5
Large doses of amphotericinB are required for cure, causing significant renal toxicity.
6
The patient progressively lost vision despite amphotericinB and 5-fluorocytosine therapy.
7
Susceptibility testing confirmed the broad activity of amphotericinB and echinocandins.
8
AmphotericinB concentrations were measured using HPLC after purification by solid phase extraction.
9
Therapy for these mycoses relies on the use of amphotericinB and 5-fluorocytosine.
10
The patients was treated with amphotericinB with regression of the skin lesions.
11
However, breakthrough fungal infections can develop despite treatment, and amphotericinB has substantial toxicity.
12
Itraconazole offers a new oral alternative to conventional amphotericinB therapy in these infections.
13
Conclusions: The choice of lipid formulation may influence amphotericinB penetration into the lung.
14
High-dose liposomal amphotericinB was effective and safe in the treatment of neonatal candidiasis.
15
All patients were treated with amphotericinB with or without flucytosine as initial therapy.
16
AmphotericinB is an essential medicine for treating this illness.